Michael Sumner
Vermögen: 46 242 $ am 30.06.2026
Vermögen: 46 242 $ am 30.06.2026
Michael Sumner is currently Chief Medical Officer & Head-Development at Inovio Pharmaceuticals, Inc. since 2022 and a Member of The Royal College of Physicians.
Former roles include Senior Director-Medical Affairs at Aventis Behring, Executive Director-Medical Affairs at Novo Nordisk Pharmaceuticals Pty Ltd., Vice President-Clinical & Medical Affairs at Shire Regenerative Medicine, Inc., Medical Manager at Novartis Pharmaceuticals UK Ltd., and Chief Medical Officer at Orexo AB from 2013 to 2022.
Education includes a doctorate from the University of London and an MBA from Henley Management College.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 20.05.2026 | 42.038 ( 0,05 % ) | 46 242 $ | 30.06.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| INOVIO PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 27.06.2022 |
The Royal College of Physicians
The Royal College of Physicians Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
| Unternehmen | Position | Ende |
|---|---|---|
| OREXO AB | Technik-/Wissenschafts-/F&E-Leiter | 26.10.2022 |
Shire Regenerative Medicine, Inc.
Shire Regenerative Medicine, Inc. BiotechnologyHealth Technology Manufactures biomedical products | Technik-/Wissenschafts-/F&E-Leiter | - |
Novo Nordisk Pharmaceuticals Pty Ltd.
Novo Nordisk Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals for diabetes care | Technik-/Wissenschafts-/F&E-Leiter | - |
Aventis Behring
Aventis Behring Pharmaceuticals: MajorHealth Technology Develops pharmaceutical and agricultural products | Technik-/Wissenschafts-/F&E-Leiter | - |
Novartis Pharmaceuticals UK Ltd.
Novartis Pharmaceuticals UK Ltd. Pharmaceuticals: MajorHealth Technology Manufactures medicines and drugs | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 9 |
|---|---|
Shire Regenerative Medicine, Inc.
Shire Regenerative Medicine, Inc. BiotechnologyHealth Technology Manufactures biomedical products | Health Technology |
Novartis Pharmaceuticals UK Ltd.
Novartis Pharmaceuticals UK Ltd. Pharmaceuticals: MajorHealth Technology Manufactures medicines and drugs | Health Technology |
Orexo AB
Orexo AB Pharmaceuticals: MajorHealth Technology Manufactures and commercializes pharmaceutical products | Health Technology |
Aventis Behring
Aventis Behring Pharmaceuticals: MajorHealth Technology Develops pharmaceutical and agricultural products | Health Technology |
University of London
University of London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops synthetic vaccines and immune therapies for cancers and infectious diseases | Health Technology |
Henley Management College
Henley Management College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Royal College of Physicians
The Royal College of Physicians Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novo Nordisk Pharmaceuticals Pty Ltd.
Novo Nordisk Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals for diabetes care | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen